Acadia Pharma (ACAD) Tops Q2 EPS by 2c
Tweet
Share
E-mail
Get Alerts ACAD Hot Sheet
Price: $23.36 +3.36%
EPS Growth %: -62.5%
Financial Fact:
Net loss per common share, basic and diluted: -0.61
Today's EPS Names:
DTGI, CRMT, MAYS, More
EPS Growth %: -62.5%
Financial Fact:
Net loss per common share, basic and diluted: -0.61
Today's EPS Names:
DTGI, CRMT, MAYS, More
Join SI Premium – FREE
Acadia Pharma (NASDAQ: ACAD) reported Q2 EPS of $0.16, $0.02 better than the analyst estimate of $0.14. Revenue for the quarter came in at $264.6 million versus the consensus estimate of $262.44 million.
For earnings history and earnings-related data on Acadia Pharma (ACAD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- MillerKnoll, Inc. (MLKN) Tops Q4 EPS by 4c
- H.B. Fuller (FUL) Tops Q2 EPS by 3c; Offers Outlook
- Micron Technology (MU) Tops Q3 EPS by $4.62, Guidance Beats
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
